Asia has intermediate-to-high prevalence and high morbidity of hepatitis B virus (HBV)
infection. The use of guideline-recommended nucleos (t) ide analogs with high barrier to …

Tenofovir alafenamide (TAF), a novel prodrug of tenofovir was developed to deliver
enhanced antiviral potency and reduced systemic toxicities by more efficient intracellular …

ABSTRACT Introduction: In April 2017 tenofovir alafenamide (TAF) was added to the list of
first-line therapies recommended for chronic hepatitis B (CHB). TAF has pharmacology …

Introduction: Tenofovir alafenamide (TAF) has recently been approved for chronic hepatitis B
(CHB). It is more stable than tenofovir disoproxil fumarate (TDF) in the plasma and can …

Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV), has been approved for the
treatment of chronic hepatitis B virus (HBV) infection. TAF has been shown to be a potent …

Background & Aims Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to
treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir …

Objectives: Results from two Phase 3 studies, through 2 years, in chronic hepatitis B
infection (CHB) showed tenofovir alafenamide (TAF) had similar efficacy to tenofovir …

Background The novel prodrug tenofovir alafenamide delivers the nucleotide reverse
transcriptase inhibitor tenofovir to target cells more efficiently at a lower dose than tenofovir …

Methods Chinese hepatitis B e antigen (HBeAg)-positive and-negative chronic hepatitis B
patients with viremia and elevated alanine aminotransferase were randomized 2: 1 to TAF or …

Background Tenofovir alafenamide (TAF) has exhibited a favourable safety profile on
estimated glomerular filtration (eGFR) and bone mineral density (BMD), but has not been …